The potential danger of suboptimal antibody responses in COVID-19

Nat Rev Immunol. 2020 Jun;20(6):339-341. doi: 10.1038/s41577-020-0321-6.


There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.

MeSH terms

  • Animals
  • Antibodies, Viral / biosynthesis*
  • Antibodies, Viral / immunology
  • Betacoronavirus / immunology*
  • COVID-19
  • COVID-19 Vaccines
  • Coronavirus Infections / immunology*
  • Coronavirus Infections / prevention & control
  • Humans
  • Mice
  • Pandemics
  • Pneumonia, Viral / immunology*
  • SARS-CoV-2
  • Viral Vaccines / adverse effects
  • Viral Vaccines / immunology*


  • Antibodies, Viral
  • COVID-19 Vaccines
  • Viral Vaccines